Zacks Investment Research upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a sell rating to a hold rating in a research note published on Monday morning.
According to Zacks, “Phibro ended second-quarter fiscal 2018 on a mixed note, with bottom line exceeding the Zacks Consensus Estimate and revenues declining marginally on a year-over-year basis. Segment-wise, a persistent decline in Mineral Nutrition segment sales is likely to prove a drag. Customer consolidation can also adversely affect Phibro’s revenues. Moreover, headwinds such as unfavorable currency movement and tough competitive scenario continue to pose threats. Over the past three months, Phibro has been trading below the broader industry. However, on a positive note, Animal Health remained the key contributing business, delivering positive growth on a year-over-year basis. We are also encouraged by the expansion in the gross margin in the reported quarter.”
Several other research firms have also issued reports on PAHC. Piper Jaffray Companies set a $41.00 price objective on Phibro Animal Health and gave the company a buy rating in a research note on Friday, October 6th. BidaskClub upgraded Phibro Animal Health from a strong sell rating to a sell rating in a research note on Saturday, January 6th. Finally, ValuEngine lowered Phibro Animal Health from a buy rating to a hold rating in a research note on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $38.25.
Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Monday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.01. The firm had revenue of $193.40 million for the quarter, compared to analyst estimates of $189.89 million. Phibro Animal Health had a return on equity of 39.76% and a net margin of 8.22%. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.36 earnings per share. equities research analysts forecast that Phibro Animal Health will post 1.57 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, December 27th. Stockholders of record on Wednesday, December 6th were paid a dividend of $0.10 per share. The ex-dividend date of this dividend was Tuesday, December 5th. This represents a $0.40 dividend on an annualized basis and a dividend yield of 1.12%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 23.53%.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Nationwide Fund Advisors grew its position in Phibro Animal Health by 1.0% during the second quarter. Nationwide Fund Advisors now owns 10,866 shares of the company’s stock worth $403,000 after buying an additional 110 shares in the last quarter. American Century Companies Inc. grew its position in Phibro Animal Health by 1.1% during the second quarter. American Century Companies Inc. now owns 18,905 shares of the company’s stock worth $700,000 after buying an additional 205 shares in the last quarter. Victory Capital Management Inc. grew its position in Phibro Animal Health by 17.6% during the second quarter. Victory Capital Management Inc. now owns 5,380 shares of the company’s stock worth $199,000 after buying an additional 807 shares in the last quarter. Thrivent Financial For Lutherans grew its position in Phibro Animal Health by 8.0% during the second quarter. Thrivent Financial For Lutherans now owns 11,310 shares of the company’s stock worth $419,000 after buying an additional 840 shares in the last quarter. Finally, Kennedy Capital Management Inc. grew its position in Phibro Animal Health by 1.4% during the second quarter. Kennedy Capital Management Inc. now owns 99,004 shares of the company’s stock worth $3,668,000 after buying an additional 1,355 shares in the last quarter. Institutional investors own 48.42% of the company’s stock.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.